


## Zandelisib

## Chemical Properties

CAS No. :	1401436-95-0
Formula:	C <sub>31</sub> H <sub>38</sub> F <sub>2</sub> N <sub>8</sub> O
Molecular Weight:	576.68
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110 $\delta$ , IC <sub>50</sub> of 3.5 nM), and with antineoplastic activity.
Targets(IC <sub>50</sub> )	PI3K
In vitro	Zandelisib inhibits PI3Ks(p110 $\alpha$ , p110 $\beta$ , p110 $\gamma$ and p110 $\delta$ with IC <sub>50</sub> s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM, respectively)[1].

## Solubility Information

Solubility	Ethanol: 2.5 mg/mL (4.34 mM),Sonication is recommended. DMSO: 33.33 mg/mL (57.8 mM),when pH Adjusted to 3 with HCl. Sonication and heating to 60°C are recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 2 mg/mL (3.47 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	1.7341 mL	8.6703 mL	17.3406 mL
5 mM	0.3468 mL	1.7341 mL	3.4681 mL
10 mM	0.1734 mL	0.867 mL	1.7341 mL
50 mM	0.0347 mL	0.1734 mL	0.3468 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Daniel P. Gold, et al. Combination therapy. WO2019183226A1.

David Brown, et al. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases. WO2014055647A1.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 34 Washington Street, Wellesley Hills, MA 02481